Atara Biotherapeutics, Inc. Altman Z-Score
ATRA|Modified Z-Score (book value) based on FY2025 data
Atara Biotherapeutics, Inc.'s Altman Z-Score of -73.54 places the company in the "distress zone" (below 1.23). Companies in this range have historically shown higher rates of financial distress (FY2025).
Based on SEC 10-K filings.
Key Data Points
- Altman Z-Score -73.54 (distress zone, below 1.8 threshold)
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Distress Zone (< 1.23)
Distress zone - elevated risk of financial difficulties
The Altman Z-Score predicts bankruptcy risk using 5 financial ratios. Learn more
Components: book value of equity, working capital, retained earnings, EBIT, and revenue-to-assets — all derived from SEC FY2025 10-K filings.
5-Factor Decomposition
| Component | Ratio | Weight | Contribution |
|---|---|---|---|
| Working Capital / Total Assets | -0.134 | 0.717 | -0.096 |
| Retained Earnings / Total Assets | -99.919 | 0.847 | -84.632 |
| EBIT / Total Assets | 1.772 | 3.107 | 5.506 |
| Book Equity / Total Liabilities | -0.655 | 0.420 | -0.275 |
| Revenue / Total Assets | 5.968 | 0.998 | 5.957 |
| Total Z-Score | -73.54 | ||
As of FY2025 · SEC 10-K · Updated Jun 24, 2026
Z-Score Zones
Safe Zone - Company is in strong financial health with low bankruptcy risk.
Grey Zone - Uncertain financial position. Requires closer monitoring.
Distress Zone - Elevated probability of financial difficulties.